| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ebb6a553affdc364c91cffe3baf12564 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 |
| filingDate |
1999-05-13^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2002-12-31^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97547c61b20027d3fc44901781c1b75f |
| publicationDate |
2002-12-31^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-6500833-B1 |
| titleOfInvention |
(+)-Hydroxyrisperidone compositions and methods |
| abstract |
Methods and compositions utilizing a compound represented by Formula III,wherein R is chosen from -OH, -P(O)(OH)2 and -SO3H, or pharmaceutically acceptable salts thereof, for the treatment of psychoses in humans are disclosed. The compounds of the present invention exhibit fewer side effects than risperidone, a lessened liability toward drug-drug interactions than risperidone and a more predictable dosing regimen than risperidone. The compounds of the invention are also useful for the treatment of emesis and withdrawal syndromes. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9320707-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9393192-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009035828-A1 |
| priorityDate |
1998-05-18^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |